Tacit Therapeutics: Funding, Investors & Team (Sep 2026)
Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
Tacit Therapeutics has raised $19.0M across 1 funding round on record, the most recent a Series A of $19.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tacit Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Tacit Therapeutics Funding Rounds
Tacit Therapeutics Founders and Leadership Team
Contact details for the Tacit Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Tacit Therapeutics Funding Compared to Other Biotechnology Startups
Tacit Therapeutics' latest round of $19.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tacit Therapeutics in Biotechnology and South San Francisco
Companies Similar to Tacit Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Tacit Therapeutics Funding FAQs
What does Tacit Therapeutics do?
Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
How much funding has Tacit Therapeutics raised?
Tacit Therapeutics has raised $19.0M across 1 round on record. The most recent is a Series A of $19.0M announced in Mar 2026.
When did Tacit Therapeutics last raise funding?
Tacit Therapeutics' most recent funding round on record is a Series A of $19.0M, announced in Mar 2026.
Who founded Tacit Therapeutics?
FundedIQ lists David Nelles (Founder) at Tacit Therapeutics.
Where is Tacit Therapeutics headquartered?
Tacit Therapeutics is based in South San Francisco, California, United States.
How many employees does Tacit Therapeutics have?
Tacit Therapeutics is in the 11-50 employee band.
How does Tacit Therapeutics' funding compare to other Biotechnology startups?
Tacit Therapeutics' latest round of $19.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Tacit Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tacit Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.